Safe Implant Technology Heads to Singapore

to Explore International MedTech Collaboration

Safe Implant Technology (SIT), a Danish MedTech company developing the patented GP5 technology, is participating in Singapore Week of Innovation and Technology (SWITCH) from 27–29 October 2026.

The company is joining an international delegation organised through the Eureka network, bringing together innovative businesses seeking new opportunities for technology development and international collaboration.

For SIT, the event represents an opportunity to engage with medical device manufacturers, researchers and technology partners around animportant challenge in implantable medical technology: the interaction between implanted materials and the human immune system.

A biological challenge with international relevance

Medical implants have advanced significantly in materials, electronics and functionality. Yet their long-term performance may also depend on how the surrounding tissue responds to the implanted material.

The foreign body response can involve inflammation and the formation of fibrotic tissue around an implant. Depending on the deviceand its intended application, these processes may influence tissue integration and performance.

Safe Implant Technology is developing GP5 as a surface-based technology designed to influence the local immune response at the interface between implants and surrounding soft tissue.

The technology builds on scientific investigations of immune-related mechanisms and subsequent preclinical studies exploring their relevance in soft-tissue environments.

From scientific research to industrial collaboration

Potential applications include implantable sensors, surgical mesh and other medical devices where long-term interaction with surrounding tissue is an important consideration.

For SIT, the next stage is about connecting scientific insights with the practical requirements of medical device development. This includes identifying relevant applications, understanding manufacturing requirements and developing the evidence needed for specific medical devices.

Claus Jarrels, Partner at Safe Implant Technology:

“We are not going to Singapore simply to present a technology. We are going to explore where a better understanding of the body’s response to implants could create real opportunities for medical device developers.

GP5 has an interesting scientific foundation, but translating that potential into medical applications requires collaboration with the companies developing the next generation of implantable devices. That is why international events like SWITCH matter to us.”

Singapore as a gateway to international opportunities

SWITCH brings together participants from international innovation ecosystems, research institutions, technology companies and investment communities.

Through its participation in the Eureka delegation, Safe Implant Technology aims to expand its international network and engage in discussions with potential technology and industrial partners.

The company is particularly interested in organisations working with implantable sensors, biomaterials and other soft-tissue medical devices where the biological interface represents an important design consideration.

Looking beyond Singapore

SIT’s participation in SWITCH forms part of its broader ambition to translate scientific insights into technologies with practical relevance for future medical devices.

While further development and application-specific validation remain essential, the company sees international collaboration as an important step toward exploring GP5’s potential.

As implantable medical technologies become more advanced, understanding the body’s response may become just as important as advancing the devices themselves.

For Safe Implant Technology, Singapore is an opportunity to contribute to that conversation and establish relationships that can support future development.

About Safe Implant Technology

Safe Implant Technology is a Danish MedTech company developing GP5, a patented surface technology designed to influence the local immune response to implants in soft tissue. The company focuses on translating scientific research into potential applications for implantable medical devices through development and industrial collaboration.